Ryung Kee Hong

Title: Innovations of Ryung Kee Hong in Angiogenesis Inhibition

Introduction

Ryung Kee Hong is a notable inventor based in Seoul, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that inhibit angiogenesis. With a total of 2 patents to his name, his work is recognized for its potential impact on medical treatments.

Latest Patents

Hong's latest patents include innovative compounds that serve as angiogenesis inhibiting agents. The first patent focuses on fumagillol derivatives and processes for preparing these compounds. These compounds are represented by a specific formula and are designed to be used in pharmaceutical compositions aimed at inhibiting angiogenesis in mammals. The second patent involves 5-demethoxyfumagillol derivatives, which also serve as angiogenesis inhibiting agents, with similar applications in pharmaceutical compositions.

Career Highlights

Ryung Kee Hong is associated with Chong Kun Dang Corporation, a prominent player in the pharmaceutical industry. His work at the company has allowed him to explore and develop groundbreaking solutions in the field of angiogenesis inhibition.

Collaborations

Hong collaborates with esteemed colleagues such as Jung Woo Kim and Sang Joon Lee. Their combined expertise contributes to the advancement of innovative pharmaceutical solutions.

Conclusion

Ryung Kee Hong's contributions to the field of angiogenesis inhibition through his patents highlight his role as a significant inventor in the pharmaceutical industry. His work continues to pave the way for new treatments that could benefit many.